menu
    • menu

    Company profile for Avenge Bio

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local an...
    Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avenge BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Strathmore Rd, STE 241 Natick, MA 01760
    Telephone
    Telephone
    (508) 290-0502
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avengebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avenge-bio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Implant shows promise in treating melanoma, pancreatic, and tumors
    Implant shows promise in treating melanoma, pancreatic, and tumors

    08 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cancer-fighting-implant-shows-promise-in-treating-melanoma-pancreatic-and-colorectal-tumors-302422515.html

    PR NEWSWIRE
    08 Apr 2025
    Share Share
    Avenge Bio to Present at the SITC 38th Annual Meeting
    Avenge Bio to Present at the SITC 38th Annual Meeting

    24 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avenge-bio-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting-301965295.html

    PR NEWSWIRE
    24 Oct 2023
    Share Share
    Avenge Bio Receives FDA Fast Track Designation for AVB-001
    Avenge Bio Receives FDA Fast Track Designation for AVB-001

    02 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avenge-bio-receives-fda-fast-track-designation-for-avb-001-a-novel-cell-therapy-leveraging-the-lococyte-immunotherapy-platform-301943619.html

    PR NEWSWIRE
    02 Oct 2023
    Share Share
    Avenge Bio Receives FDA Orphan Drug Designation for AVB-001
    Avenge Bio Receives FDA Orphan Drug Designation for AVB-001

    15 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avenge-bio-receives-fda-orphan-drug-designation-for-avb-001-for-the-treatment-of-mesothelioma-301851339.html

    PR NEWSWIRE
    15 Jun 2023
    Share Share
    BioCentriq Completes Tech Transfer From Avenge Bio
    BioCentriq Completes Tech Transfer From Avenge Bio

    18 Jan 2023

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2023-01-18/biocentriq-completes-tech-transfer-from-avenge-bio/?widget=listSection

    CONTRACT PHARMA
    18 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search